These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11075290)

  • 1. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro.
    Rabe T; Kowald A; Ortmann J; Rehberger-Schneider S
    Gynecol Endocrinol; 2000 Aug; 14(4):223-30. PubMed ID: 11075290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestogens with antiandrogenic properties.
    Raudrant D; Rabe T
    Drugs; 2003; 63(5):463-92. PubMed ID: 12600226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dienogest.
    Foster RH; Wilde MI
    Drugs; 1998 Nov; 56(5):825-33; discussion 834-5. PubMed ID: 9829156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sex steroids on skin 5 alpha-reductase activity in vitro.
    Cassidenti DL; Paulson RJ; Serafini P; Stanczyk FZ; Lobo RA
    Obstet Gynecol; 1991 Jul; 78(1):103-7. PubMed ID: 1828548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selectivity of a new progestin.
    Phillips A
    Acta Obstet Gynecol Scand Suppl; 1990; 152():21-4. PubMed ID: 2189281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells.
    Prifti S; Lelle I; Strowitzki T; Rabe T
    Gynecol Endocrinol; 2004 Jul; 19(1):18-21. PubMed ID: 15625768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
    Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].
    Oettel M; Carol W; Gräser T; Klinger G; Mellinger U; Moore C; Schindler AE; Winkler UH
    Zentralbl Gynakol; 1997; 119(12):597-606. PubMed ID: 9483810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.